One step closer to MU final rule

Beth Walsh | | Health Exec | EMR/EHR

The combined rules for Meaningful Use Stages 2 and 3 went to the Office of Management and Budget (OMB) on Sept. 3.

A rule going to the OMB is the final step before publication.

Stage 2 modifications have been much discussed, including a 90-day 2015 reporting period, a switch to aligning the reporting period to the calendar year and a reduced patient engagement requirement criticized as virtually useless.

It's unclear whether the action is related to calls for clarity and finalization of the regulations from a range of stakeholders. Most recently, the Medical Group Management Association called for a final rule so practices can adequately prepare.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Related Content

Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup